Celltrion Inc
KRX:068270
Intrinsic Value
Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. [ Read More ]
The intrinsic value of one Celltrion Inc stock under the Base Case scenario is 112 737.14 KRW. Compared to the current market price of 176 600 KRW, Celltrion Inc is Overvalued by 36%.
Valuation Backtest
Celltrion Inc
Run backtest to discover the historical profit from buying and selling Celltrion Inc stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Celltrion Inc
Current Assets | 5T |
Cash & Short-Term Investments | 731.8B |
Receivables | 975.7B |
Other Current Assets | 3.3T |
Non-Current Assets | 14.9T |
Long-Term Investments | 135.4B |
PP&E | 1.2T |
Intangibles | 13.3T |
Other Non-Current Assets | 222.1B |
Current Liabilities | 2.5T |
Accounts Payable | 50.9B |
Accrued Liabilities | 205.7B |
Short-Term Debt | 1.6T |
Other Current Liabilities | 606.4B |
Non-Current Liabilities | 466.3B |
Long-Term Debt | 107.1B |
Other Non-Current Liabilities | 359.2B |
Earnings Waterfall
Celltrion Inc
Revenue
|
2.2T
KRW
|
Cost of Revenue
|
-1.1T
KRW
|
Gross Profit
|
1.1T
KRW
|
Operating Expenses
|
-400.4B
KRW
|
Operating Income
|
651.5B
KRW
|
Other Expenses
|
-115.8B
KRW
|
Net Income
|
535.6B
KRW
|
Free Cash Flow Analysis
Celltrion Inc
Profitability Score
Profitability Due Diligence
Celltrion Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Celltrion Inc's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Celltrion Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Celltrion Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Celltrion Inc
According to Wall Street analysts, the average 1-year price target for Celltrion Inc is 236 215 KRW with a low forecast of 160 590 KRW and a high forecast of 315 000 KRW.
Shareholder Return
Price
Celltrion Inc
Average Annual Return | 6.73% |
Standard Deviation of Annual Returns | 61.51% |
Max Drawdown | -64% |
Market Capitalization | 36.6T KRW |
Shares Outstanding | 218 050 000 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Celltrion, Inc. engages in the development, manufacture and distribution of pharmaceuticals. The company is headquartered in Incheon, Incheon. The company went IPO on 2005-07-19. The firm operates its business through two segments. The Bio Pharmaceutical segment produces and sells protein therapeutics such as anticancer drugs. In addition, this Segment develops monoclonal antibodies(mABs) that are used to treat chronic autoimmune diseases such as arthritis and severe diseases such as breast and colon cancer. The Chemical Pharmaceutical segment is mainly engaged in the manufacture and sale of chemical drugs. In addition, the Segment sells bio drugs, and provides services such as data analysis. The firm's main products include liver and bowel medicines and other generics. The main products sold by the Company include autoimmune disease treatment agents, anti-malignant tumor drugs and other products. The firm sells its products in domestic and overseas markets such as Europe and the United States.
Contact
IPO
Employees
Officers
The intrinsic value of one Celltrion Inc stock under the Base Case scenario is 112 737.14 KRW.
Compared to the current market price of 176 600 KRW, Celltrion Inc is Overvalued by 36%.